［1］Levy G.Pharmacologic target‐mediated drug disposition［J］.Clin Pharmacol Ther,1994,56(3):248-252.
［2］Dua P,Hawkins E,Van PDG.A tutorial on target-mediated drug disposition (TMDD) models［J］.CPT Pharmacometrics Syst Pharmacol,2015,4(6):324-337.
［3］Wang Y,Booth B,Rahman A,et al.Toward greater insights on pharmacokinetics and exposur-response relationships for therapeutic biologics in oncology drug development［J］.Clin Pharmacol Ther,2017,101(5):582.
［4］Mager DE,Jusko WJ.General pharmacokinetic model for drugs exhibiting target-mediated drug disposition［J］.J Pharmacokinet Pharmacodyn,2001,28(6):507-532.
［5］Cao Y, Jusko WJ. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model［J］. J Pharmacokinet Pharmacodyn, 2014, 41(6):571-580.
［6］Kagan L, Turner MR, Balu-Iyer SV, et al. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats［J］. Pharm Res, 2012, 29(2):490-499.
［7］Yan X, Chen Y, Krzyzanski W. Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor［J］. J Pharmacokinet Pharmacodyn, 2012, 39(5):543-560.
［8］Gibiansky L, Gibiansky E. Target-mediated drug disposition model for drugs that bind to more than one target［J］. J Pharmacokinet Pharmacodyn, 2010, 37(4):323-346.
［9］Krippendorff BF, Kuester K, Kloft C, et al. Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis［J］. J Pharmacokinet Pharmacodyn, 2009, 36(3):239-260.
［10］Krippendorff BF, Oyarzún DA, Huisinga W. Predicting the F(ab)mediated effect of monoclonal antibodies in vivo by combining celllevel kinetic and pharmacokinetic modelling［J］. J Pharmacokinet Pharmacodyn, 2012, 39(2):125-139.
［11］Xiao JJ, Krzyzanski W, Wang YM, et al. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys［J］. AAPS J , 2010, 12(4):646-657.
［12］Ruixo JJP, Ma P, Chow AT. The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics［J］. AAPS J, 2013, 15(1):172-182.
［13］Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition［J］. Pharm Res, 2005, 22(10):1589-1596.
［14］Peletier LA, Gabrielsson J. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification［J］. J Pharmacokinet Pharmacodyn, 2012, 39(5):429-451.
［15］Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models［J］. J Pharmacokinet Pharmacodyn, 2010, 37(1):25-47.
［16］Gibiansky L, Gibiansky E, Kakkar T, et al. Approximations of the target-mediated drug disposition model and identifiability of model parameters［J］. J Pharmacokinet Pharmacodyn, 2008, 35(5):573-591.
［17］Ma P. Theoretical considerations of target-mediated drug disposition models: simplifications and approximations［J］. Pharm Res, 2012, 29(3):866-882.
［18］Wagner JG.A new generalized nonlinear pharmacokinetic model and its implications［M］. //Biopharmaceutics and relevant pharmacokinetics,drug Intelligence publications.Hamilton:Hamilton Press,1971:302-317.
［19］Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition［J］. Pharm Res, 2005, 22(10):1589-1596.
［20］Abraham AK, Krzyzanski W, Mager DE. Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition［J］. Aaps Journal, 2007, 9(2):E181-E189.
［21］Gibiansky L, Gibiansky E, Kakkar T, et al. Approximations of the target-mediated drug disposition model and identifiability of model parameters［J］. J Pharmacokinet Pharmacodyn, 2008, 35(5):573-591.
［22］Peletier LA, Gabrielsson J. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification［J］. J Pharmacokinet Pharmacodyn, 2012, 39(5):429-451.
［23］季双敏, 朱校. 靶点介导的药物处置模型在单克隆抗体药物研发中应用的探讨［J］. 中国临床药理学与治疗学, 2018, 23(3):241-246.
［24］Betts AM, Clark TH, Yang J, et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf1 antibody for osteoporosis ［J］. J Pharmacol Exp Ther, 2010, 333(1):2-13.
［25］Luu KT,Bergqvist S,Chen E,et al. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition［J］.J Pharmacol Exp Ther, 2012, 341(3): 702-708.